Cargando…

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to Apr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal, Mehmet Sinan, Ulu, Bahar Uncu, Uzay, Ant, Akay, Olga Meltem, Beşışık, Sevgi, Yenerel, Mustafa Nuri, Çelik, Serhat, Kaynar, Leylagül, Yücel, Orhan Kemal, Deveci, Burak, Sönmez, Mehmet, Mehtap, Özgür, Beköz, Hüseyin Saffet, Sunu, Cenk, Salim, Ozan, Ulaş, Turgay, Kartı, Sami, Altuntaş, Fevzi, Ferhanoğlu, Burhan, Tuğlular, Tülin Fırat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676783/
https://www.ncbi.nlm.nih.gov/pubmed/36401621
http://dx.doi.org/10.1007/s00277-022-05052-x
Descripción
Sumario:Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1–2 of each cycle. Median age at Pola-BR initiation was 55 (19–84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3–4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.